Skip to content

Lyra Therapeutics, Inc.

LYRA

CIK 0001327273

← back to feed
Revenue (TTM)
$586K
−74.1% YoY FY Mar 2026
Net Income (TTM)
−$33.84M
+69.0% YoY FY Mar 2026
EPS Diluted (TTM)
−$18.09
+74.0% YoY FY Mar 2026
Gross Margin
—
FY Mar 2026
Operating Margin
-6,202.4%
FY Mar 2026
Net Margin
-5,774.9%
FY Mar 2026
Free Cash Flow (TTM)
−$62.5M
FY Mar 2026
Cash
$15.89M
FY Mar 2026
Total Debt
—
FY Mar 2026
Shares Outstanding
1.77M sh
FY Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings